Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte CorpfiledCriticalIncyte Corp
Publication of CR9103ApublicationCriticalpatent/CR9103A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invencion se refiere a inhibidores de 11-B hidroxil esteroide deshidrogenasa tipo 1, antagonistas del receptor mineralocorticoide (MR), y composiciones farmaceuticas de los mismos. Los compuestos de la invencion pueden ser utiles en el tratamiento de varias enfermedades asociadas con la expresion o actividad de 11-B hidroxil esteroide deshidrogenasa tipo 1 y/o enfermedades asociadas con exceso de aldosterona.The present invention relates to 11-B hydroxyl steroid dehydrogenase type 1 inhibitors, mineralocorticoid (MR) receptor antagonists, and pharmaceutical compositions thereof. The compounds of the invention may be useful in the treatment of various diseases associated with the expression or activity of 11-B hydroxy steroid dehydrogenase type 1 and / or diseases associated with excess aldosterone.
CR9103A2004-11-102007-05-03
LACTAMA COMPOUNDS AND THEIR USES AS PHARMACEUTICS
CR9103A
(en)
Compounds derived from piperidine, which have modulating activity on the activity of the gpr 119 receptor; pharmaceutical composition comprising said compounds; and its use in the treatment of diseases such as type 1 and 2 diabetes, hyperpidemia, coronary heart disease, obesity and erectile dysfunction.
Isoxazolo-pyridazine derived compounds; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cognitive disorders such as Alzheimer's
Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
COMPOUNDS DERIVED FROM 2-AMINO-OXAZOLINAS; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DEPRESSION, ANXIETY, STRESS, BIPOLAR DISORDER, AMONG OTHERS.
Compounds derived from piperidine 1,4 heterocycle substituted, procedure to prepare these compounds, pharmaceutical composition comprising them and their use for pain therapy and the treatment of diseases such as Alzheimer's, schizophrenia, anxiety and depression.
Polycyclic pyrazolyl n-sulfonamido derivatives; inhibitors of the release and synthesis of beta-amyloid and y-secretase peptides; pharmaceutical composition comprising them; and its uses in the treatment of Alzheimer's, Parkinson's, Down syndrome, among others.